Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug cocktails aim to fight advanced lung cancer

NCT ID NCT05676931

Disease control Sponsor: Gilead Sciences Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing several immunotherapy drug combinations in people with advanced non-small cell lung cancer that has spread. The goal is to see if these combinations can shrink tumors and improve survival. About 400 participants will receive different drug mixes, including domvanalimab, zimberelimab, and chemotherapy. The study is currently active but no longer recruiting new participants.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
domvanalimab, quemliclustat, zimberelimab, docetaxel, platinum-based doublet
What this could lead to
If successful, this could lead to more effective treatment options for advanced lung cancer, potentially improving survival and quality of life.
What could go wrong
This is an early-phase trial with only 400 participants, so results may not apply to all patients. Immunotherapy combinations can cause serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 400 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2023

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histologically or cytologically documented Stage IV metastatic, NSCLC * Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 1 * At least one measurable target lesion per RECIST v1.1. * Adequate organ function * Participants must be willing to provide adequate tumor tissue Exclusion Criteria: * Underlying medical conditions that, in the Investigator's or Sponsor's opinion, will make the administration of Investigational Product(s) (IPs) hazardous * Use of any live vaccines against infectious diseases within 28 days of first dose of IP(s). * Use of supra-physiologic doses of corticosteroids (\> 10 mg/day of oral prednisone or equivalent) or immunosuppressive medications ≤ 14 days before the initiation of study treatment (absorbable topical corticosteroids are not excluded). * Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial. * Any active autoimmune disease or a documented history of autoimmune disease or syndrome that required systemic treatment in the past 2 years (ie, with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs), except for vitiligo or resolved childhood asthma/atopy NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced non-small cell lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Advanced non-small cell lung cancer

Contacts and locations

Locations

  • Asan Medical Center

    Seoul, 138-736, South Korea

  • Azienda Sanitaria Territoriale Pesaro Urbino (AST PU)

    Pesaro, Italy

  • Barts Health NHS Trust St Bartholomew's Hospital

    London, W1G 6AF, United Kingdom

  • CHU Bordeaux Centre Francois Magendie Hôpital du Haut Lévèque

    Bordeaux, 33604, France

  • Cancer Research SA Pty Ltd

    Adelaide, South Australia, 5000, Australia

  • Caucasus Medical Center

    Tbilisi, Georgia

  • Centrum Onkologii - Instytut im. Marii Sk?odowskiej-Curie

    Warsaw, Poland

  • Chonam National University Hwasun Hospital

    Hwasun-gun, 58128, South Korea

  • Chungbuk National University Hospital

    Cheongju-si, 28644, South Korea

  • Complejo Hospitalario Universitario Insular Materno Infantil De Gran Canaria

    Las Palmas de Gran Canaria, 35016, Spain

  • E-DA Healthcare Group E-DA Hospital

    Kaoshiung, 970, Taiwan

  • Florida Cancer Specialists (Administration and Drug Shipment)

    The Villages, Florida, 32163, United States

  • Fondazione IRCCS Istituto Nazionale dei tumori di Milano

    Rome, Italy

  • Hematology Oncology Associates Of The Treasure Coast

    Port Saint Lucie, Florida, 34952, United States

  • Henry Ford Hospital

    Detroit, Michigan, 48202, United States

  • Hopital FOCH

    Suresnes, France

  • Hospices Civils de Lyon Centre Hospitalier Lyon Sud

    Lyon, 69495, France

  • Hospital 9 de Octubre Vithas Valencia

    Valencia, 46015, Spain

  • Hospital Quirónsalud Málaga

    Málaga, Spain

  • Hospital Universitari Mutua Terrassa

    Barcelona, 8221, Spain

  • Hospital Universitario De La Virgen De Valme

    Seville, 41001, Spain

  • Hospital Universitario Lucus Augusti

    Lugo, Spain

  • Hospital Universitario Virgen Macarena

    Seville, 41009, Spain

  • Hospital Universitario y Politécnico la Fe

    Valencia, 46026, Spain

  • Hospital de la Santa Creu i Sant Pau

    Barcelona, 8041, Spain

  • Hualien Tzu Chi Hospital Buddhist Tzu Chi Medical Foundation

    Hualien City, 970, Taiwan

  • Institut De Cancerologie Strasbourg Europe ICANS

    Strasboug, 67033, France

  • Israel Georgian Medical Research Clinic Healthycore

    Tbilisi, Georgia

  • Istituto Oncologico Veneto IRCCS

    Padova, 35128, Italy

  • Istituto Romagnolo per lo Studio dei Tumori-Dino Amadori - IRST

    Meldola, Italy

  • JSC K. Eristavi National Center of Experimental and Clinical Surgery

    Tbilisi, Georgia

  • Korea University Guro Hospital

    Seoul, 08308, South Korea

  • LTD High Technology Hospital Medcenter

    Batumi, Georgia

  • Ltd Pineo Medical Ecosystem

    Tbilisi, Georgia

  • Mackey Memorial Hospital

    Taipei, 104, Taiwan

  • Medical Oncology Associated, PS (dba Summit Cancer Centers)

    Spokane, Washington, 99208, United States

  • Medpolonia Sp. Z.o.o.

    Poznan, Poland

  • Memorial Cancer Institute at Memorial Regional Hospital

    Hollywood, Florida, 33021, United States

  • National Taiwan University Hospital Yumlin Branch

    Yunlin County, Taiwan

  • Northwestern Memorial Hospital

    Chicago, Illinois, 60611, United States

  • Ochsner Clinic Foundation

    Jefferson, Louisiana, 70121, United States

  • Pindara Private Hospital

    Benowa, Queensland, 4217, Australia

  • Samsung Changwon Hospital

    Changwon-Si, South Korea

  • Sir Charles Gairdner Hospital

    Nedlands, Western Australia, 6009, Australia

  • Szpitale Pomorskie sp. z o.o

    Gdynia, Poland

  • Taipei Medical University - Shuang Ho Hospital, Ministry of Health and Welfare

    New Taipei City, 23561, Taiwan

  • The Border Cancer Hospital

    Albury, New South Wales, Australia

  • UOMI Cancer Centre

    Barcelona, Spain

  • University of Alabama at Birmingham (UAB)

    Birmingham, Alabama, 35294, United States

  • University of California San Diego (UCSD)

    La Jolla, California, 92093, United States

  • Uniwersyteckie Centrum Kliniczne, im. prof. K. Gibińskiego

    Katowice, Poland

  • Virginia Cancer Specialists, PC

    Fairfax, Virginia, 22031, United States

  • stituto Nazionale per lo Studio e la Cura dei Tumori

    Milan, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.